Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 46
1996 41
1997 32
1998 25
2000 46
2001 19
2002 37
2003 65
2004 76
2005 72
2006 77
2007 123
2008 191
2009 251
2010 212
2011 314
2012 275
2013 449
2014 423
2015 366
2016 320
2017 385
2018 346
2019 329
2020 452
2021 476
2022 406
2023 308
2024 122

Text availability

Article attribute

Article type

Publication date

Search Results

4,606 results

Results by year

Filters applied: . Clear all
Page 1
Editors in transition.
Droller MJ. Droller MJ. Urol Oncol. 2024 Jan;42(1):1-2. doi: 10.1016/j.urolonc.2023.11.011. Urol Oncol. 2024. PMID: 38135357 No abstract available.
The perfect storm.
Caram MEV. Caram MEV. Urol Oncol. 2023 Sep;41(9):361-362. doi: 10.1016/j.urolonc.2023.06.001. Epub 2023 Jul 1. Urol Oncol. 2023. PMID: 37400354 Review. No abstract available.
Letter to editor.
Patel NB, Ghani KR. Patel NB, et al. Urol Oncol. 2024 Mar;42(3):35. doi: 10.1016/j.urolonc.2023.09.011. Epub 2023 Oct 12. Urol Oncol. 2024. PMID: 37833098 No abstract available.
Antibody-drug conjugates for urothelial carcinoma.
Thomas J, Sun M, Getz T, Ho B, Nauseef JT, Tagawa ST. Thomas J, et al. Urol Oncol. 2023 Oct;41(10):420-428. doi: 10.1016/j.urolonc.2023.06.006. Epub 2023 Jul 6. Urol Oncol. 2023. PMID: 37419845 Review.
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study.
Lowentritt B, Pilon D, Waters D, Rossi C, Muser E, Kurteva S, Shah A, Khilfeh I, Du S, Ellis L, Lefebvre P, Brown G. Lowentritt B, et al. Urol Oncol. 2023 May;41(5):252.e19-252.e27. doi: 10.1016/j.urolonc.2023.03.013. Epub 2023 Apr 19. Urol Oncol. 2023. PMID: 37080833 Free article.
Steroidogenesis in castration-resistant prostate cancer.
Shiota M, Endo S, Blas L, Fujimoto N, Eto M. Shiota M, et al. Urol Oncol. 2023 May;41(5):240-251. doi: 10.1016/j.urolonc.2022.10.018. Epub 2022 Nov 11. Urol Oncol. 2023. PMID: 36376200 Review.
Had we touched the finishing line!
Verma M, Kukreja D, Singhal S. Verma M, et al. Urol Oncol. 2022 Oct;40(10):462. doi: 10.1016/j.urolonc.2022.07.003. Epub 2022 Aug 19. Urol Oncol. 2022. PMID: 35995697 No abstract available.
4,606 results